Condition

NSCLC Stage IIIB (2)

NSCLC Stage IIIC (2)

NSCLC Stage IV (2)

EGFR Positive Non-Small Cell Lung Cancer (1)

Recurrent NSCLC (1)

Overall Status

Active, not recruiting (1)

Recruiting (1)

Sign in for free

Phase

phase 1/phase 2 (1)

phase 2 (1)

Sponsor

National Cancer Centre, Singapore (1)

Shanghai Chest Hospital (1)

Collaborator

Anhui Provincial Hospital (1)

Pfizer (1)

The Affiliated Hospital of Qingdao University (1)

Zhejiang University (1)

Intervention

anlotinib (1)

cadonilimab (1)

dacomitinib (1)

docetaxel (1)

Study Documents

Intervention Type

drug (2)

Funder Type

Other (2)

Study Type

Interventional (2)

nsclc stage iiic

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

NSCLC Stage IV, NSCLC Stage IIIB, NSCLC Stage IIIC Trial in China (Cadonilimab, Anlotinib, Docetaxel)

Recruiting

NSCLC Stage IV
+2 more

Cadonilimab
+2 more

Hefei, Anhui, China
+4 more

Apr 15, 2023

NSCLC Stage IIIB, NSCLC Stage IIIC, NSCLC Stage IV Trial in Worldwide (Dacomitinib)

Active, not recruiting

NSCLC Stage IIIB
+4 more

Dacomitinib

Hong Kong, Hong Kong
+8 more

Jan 10, 2023